Systemic increase in IL-26 is associated with severe COVID-19 and comorbid obstructive lung disease
Systemic IL-26 is involved in severe COVID-19, especially in males and patients with comorbid obstructive lung disease. These findings argue that systemic IL-26 has pathogenic and antiviral relevance, as well as biomarker potential.
Authors
- Martin K. Stengelin (ORCID: https://orcid.org/0000-0002-7298-2213)
- Eduardo I. Cardenas (ORCID: https://orcid.org/0000-0001-5973-5675)
- Jacob N. Wohlstadter (ORCID: https://orcid.org/0009-0000-4467-6895)
- Anders Lindén (ORCID: https://orcid.org/0000-0003-1258-2928)
- Salvia Misaghian
- Magnus Gisslén (ORCID: https://orcid.org/0000-0002-2357-1020)
- Josefina Robertson (ORCID: https://orcid.org/0000-0002-2167-6822)
- George B. Sigal (ORCID: https://orcid.org/0000-0001-7149-6400)
- Mingyue Wang (ORCID: https://orcid.org/0000-0001-9370-3896)
- Jermaine Brown
Institutions
- Public Health Agency of Sweden (SE)
- Karolinska University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Region Västra Götaland (SE)
- Meso Scale Discovery (United States) (US)
- University of Gothenburg (SE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-04
- DOI
- https://doi.org/10.3389/fimmu.2024.1434186
- Citations
- 4
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- Hjärt-Lungfonden
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet